The risks of medical treatment of prolactinoma.
Cabergoline
/ therapeutic use
Dopamine Agonists
/ adverse effects
Drug-Related Side Effects and Adverse Reactions
/ epidemiology
Fibrosis
/ chemically induced
Heart Valve Diseases
/ chemically induced
Humans
Neurosurgical Procedures
/ adverse effects
Pituitary Neoplasms
/ drug therapy
Prolactinoma
/ drug therapy
Substance-Related Disorders
/ epidemiology
Addiction
Cabergoline
Cardiac valvular fibrosis
Chirurgie transsphénoïdale
Prolactinoma
Prolactinome
Transsphenoidal surgery
Valvulopathie
Journal
Annales d'endocrinologie
ISSN: 2213-3941
Titre abrégé: Ann Endocrinol (Paris)
Pays: France
ID NLM: 0116744
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
accepted:
16
12
2020
pubmed:
30
12
2020
medline:
27
10
2021
entrez:
29
12
2020
Statut:
ppublish
Résumé
First-line treatment of prolactinoma is usually medical, based on dopamine agonists receptors, mainly cabergoline. The classical side-effects of cabergoline (low blood pressure and nausea) have been well known since it was first introduced. Other side-effects, however, are more controversial or simply less frequent, but need to be considered during monitoring. This review will focus on these side-effects: cardiac valvular fibrosis, pleural, pericardial and retroperitoneal fibrosis, addictive/compulsive behaviors, and risks secondary to significantly decreased tumor volume. We will also describe how such side-effects should be monitored and managed. In our opinion, the low prevalence of these side-effects should not cast doubt on the role of cabergoline in the therapeutic algorithm of prolactinoma.
Identifiants
pubmed: 33373604
pii: S0003-4266(20)31318-4
doi: 10.1016/j.ando.2020.12.008
pii:
doi:
Substances chimiques
Dopamine Agonists
0
Cabergoline
LL60K9J05T
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-19Informations de copyright
Copyright © 2021 Elsevier Masson SAS. All rights reserved.